Literature DB >> 7237892

Effects of growth hormone on antipyrine kinetics in children.

A B Rifkind, P Saenger, L S Levine, J Pareira, M I New.   

Abstract

The kinetics of antipyrine, a drug used as a clinical indicator of hepatic drug-metabolizing enzyme activity, were examined in children after short- (5 days to 1 wk) or long-term (6 wk to 1 yr) treatment with human growth hormone (hGH). After short-term treatment the mean volume of distribution of antipyrine (aVd) (also a measure of total body water) increased from 0.49 to 0.58 l/kg (p less than 0.005). The mean aVd after long-term treatment did not differ from the mean pretreatment value, but it rose in three of the eight subjects examined. Neither the mean serum half-life (t 1/2) nor the metabolic clearance rate of antipyrine for the group as a whole was altered after short- or long-term treatment with hGH. However, t 1/2 rose to 135% to 151% of control value in three of nine children and decreased to 63% of control value in one after short-term treatment, while after long-term treatment it rose to 128% to 176% of control value in four of eight children. The results indicate that hGH can increase total body water and should be used cautiously in children with impaired cardiac, renal, or hepatic function. The data further suggest that hGH may alter antipyrine t 1/2 in some children. The variable nature of the changes precludes any uniform prediction about growth hormone effects on drug metabolism, but it may be necessary in some children to modify the dosage of other drugs administered with hGH.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237892     DOI: 10.1038/clpt.1981.137

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

2.  Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.

Authors:  M W Teunissen; G J Bruining; B M De Jongh; E W Tenkate-Westerhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

4.  Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.

Authors:  Noël Knops; Jean Herman; Maria van Dyck; Yasaman Ramazani; Edward Debbaut; Rita van Damme-Lombaerts; Elena Levtchenko; Lambertus P van den Heuvel; Steffen Fieuws; Dirk Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-12-13       Impact factor: 4.335

5.  Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency.

Authors:  M J Kennedy; D A Davis; N Smith; A Gaedigk; R E Pearce; G L Kearns
Journal:  Clin Pharmacol Ther       Date:  2008-10-08       Impact factor: 6.875

Review 6.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.